Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 2

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1

Magic bullets ? monoclonal antibodies in acute leukaemias and non-Hodgkin lymphomas treatment

100%
Luczynski W., Krawczuk-Rybak M.
Postępy Higieny i Medycyny Doświadczalnej
|
2002
|
vol. 56
|
issue 6
789-801
EN
Because of high percent of failures in haematologic malignancies treatment there is a need of discovering new drugs. One of the new approaches are monoclonal antibodies, which target specific cluster differentiation antigens on tumor cells. Rituximab is an anti-CD20 antibody used in non-Hodgkin lymphoma, alemtuzumab - in B chronic lymphocytic leukaemia, gemtuzumab ozogamicin ? in non-lymphoblastic leukaemia, tositumomab and ibritumomab are monoclonal antibodies binded with radiopharmaceutics and are used in non-Hodgkin lymphomas.
2

Assessment of selected costimulatory, adhesion, and activatory molecules and cytokines of Th1/Th2 balance in acute lymphoblastic leukemia in children

81%
Luczynski W., Stasiak-Barmuta A., Krawczuk-Rybak M., Malinowska I.
Archivum Immunologiae et Therapiae Experimentalis
|
2005
|
vol. 53
|
issue 4
357-363
EN
Recent years have seen a rise in the importance of cytokine production and co-stimulatory/activatory molecule expression in the immune response in leukemia. The aim of our study was to assess the function of T lymphocytes in children with acute lymphoblastic leukemia (ALL) during remission induction based on selected cytokine and co-stimulatory/activatory molecule expression. The study group consisted of 50 children with ALL (B cell precursor). Peripheral blood samples were taken before treatment (day 0), after the prednisone prophase (day 8), and during (day 15) and after (day 33) remission induction. The percentages of T cells with interferon (IFN)-g (Th1), interleukin (IL)-4 (Th2) and IL-2 receptor (IL-2R), CD28, CTLA-4, CD38, ICAM-1, and HLA-DR expression were assessed by tricolor flow cytometry. At the time of diagnosis we noted higher percentages of T cells with adhesion molecule ICAM-1, activation molecule CD38 expression, and an increased population of Th2 cells (IL-4) compared with the control group. During and after remission induction we observed a decreased population of CD38+ T cells, elevated percentages of helper T lymphocytes with IL-2R expression, and a rise in helper T lymphocytes producing IFN-g (Th1). During fever/infection, higher levels of activated T lymphocytes (CD4+HLA-DR+, CD8+HLA-DR+), a rise in Th1, and no change in Th2 populations were observed. The results suggest T cell activation and Th2 predominance at the time of diagnosis and during remission induction in ALL in children. These results confirm the involvement of cellular immunity in the leukemic process and can be used in immune therapy in leukemia.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.